After empagliflozin, an SGLT2 inhibitor, showed reduced cardiac events in patients with DM [1], the use of SGLT2 inhibitors has been expanded to treat heart failure and chronic kidney disease [2]. This evidence concerns the gene SLC5A2 and diabetes mellitus.